Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome

American Journal of Epidemiology

Volumn 152, Issue 10, 2000, Pages 897-907

  Sakkinen, Pamela A ^a   Wahl, Patricia ^b   Cushman, Mary ^a   Lewis, Michael R ^a   Tracy, Russell P ^a,c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

Aged; Aged, 80 and over; Factor analysis, statistical; Hemostasis; Inflammation; Insulin resistance; Metabolism; Multivariate analysis

Indexed keywords

FIBRINOGEN; GLUCOSE; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTEIN; VITAMIN K GROUP;

AGED; AGING; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLUSTER ANALYSIS; DISEASE ASSOCIATION; FACTORIAL ANALYSIS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; NORMAL HUMAN; OBESITY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIGENS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; FACTOR ANALYSIS, STATISTICAL; FACTOR VII; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS;

EID: 0034669480     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/152.10.897     Document Type: Article

References (85)

1. Role of insulin resistance in human disease
2. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
3. Haemostatic function and cardiovascular death: Early results of a prospective study
4. Antithrombin and atherosclerosis in the Rotterdam Study
5. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris
6. Thrombosis in the young: Effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors
7. Increased fibrinogen levels in the offspring of hypertensive men: Relation with hyperinsulinemia and the metabolic syndrome
8. Cardiovascular risk factors: Interactive effects of lipids, coagulation and fibrinolysis
9. Multivariate analysis of the insulin resistance syndrome in women
10. Factor analysis of proposed components of the insulin resistance syndrome
11. Risk variable clustering in the insulin resistance syndrome: The Framingham Offspring Study
12. Does insulin resistance unite the separate components of the insulin resistance syndrome? Evidence from the Miami Community Health Study
13. Factors of the insulin resistance syndrome in nondiabetic and diabetic elderly Japanese-American men
14. Associations of smoking, alcohol and physical activity with risk factors for coronary heart disease and diabetes in the first follow-up cohort of the Heart Disease and Diabetes Risk Indicators in a Screened Cohort study (HDDRISC-1)
15. Risk factor clustering in the insulin resistance syndrome: The Strong Heart Study
16. Factors of the metabolic syndrome: Baseline interrelationships in the first follow-up cohort of the HDDRISC Study (HDDRISC-1). Heart Disease and Diabetes Risk Indicators in a Screened Cohort
17. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk
18. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: The Bogalusa Heart Study
19. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men
20. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study
21. Increased plasma plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis
22. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
23. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease
24. Characteristics of the insulin resistance syndrome in a Japanese population: The Jichi Medical School Cohort Study
25. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM
26. The Cardiovascular Health Study: Design and rationale
27. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study
28. Laboratory methods and quality assurance in the Cardiovascular Health Study
29. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens
30. The measurement of fibrinogen in population-based research: Studies on instrumentation and methodology
31. Methods for determining fibrinopeptide A
32. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease
33. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
34. Prothrombin fragment 1.2
35. 2-antiplasmin complex in human plasma - Application to the detection of in vivo activation of the fibrinolytic system
36. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction
37. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis
38. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunonorbent assay
39. The application of electronic computers to factor analysis
40. Evidence that insulin resistance does not unify metabolic cardiovascular disease risk variable clustering: The Framingham Offspring Study
41. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes
42. Atherosclerosis, thrombosis, and inflammation: A problem of linkage
43. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
44. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: A potential risk factor for vascular disease
45. The adipocyte and hemostatic balance in obesity: Studies of PAI-1
46. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
47. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
48. Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells
49. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
50. Hemostatic gene expression and vascular disease in obesity: Insights from studies of genetically obese mice
51. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo
52. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
53. The expression of TNF alpha by human muscle: Relationship to insulin resistance
54. Expression of plasminogen activator inhibitor type I in genotyped human endothelial cell cultures: Genotype-specific regulation by insulin
55. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids
56. Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue
57. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients
58. Increased prothrombin fragment 1+2 and D-dimer in first-degree relatives of type 2 diabetic patients: Prethrombotic state in relatives of type 2 diabetic patients
59. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
60. Haemostatic risk factors for cardiovascular diseases
61. Epidemiological evidence for inflammation in cardiovascular disease
62. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X
63. Atherosclerosis - An inflammatory disease
64. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function
65. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: Central role of tumor necrosis factor-alpha
66. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance
67. Modulation of insulin activities by leptin
68. Is leptin the link between obesity and insulin resistance?
69. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): A cohort study
70. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
71. Fibrinogen is an independent risk factor for myocardial infarction and death in elderly men: The Cardiovascular Health Study (CHS)
72. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease
73. The epidemiology of haemostatic and other variables in coronary artery disease
74. Fibrinogen and risk of cardiovascular disease: The Framingham Study
75. Haemostatic function and cardiovascular death: Early results of a prospective study
76. Issues relating to normalization of body fat content in men and women
77. Statistical considerations regarding the use of ratios to adjust data
78. Mathematical contributions to the theory of evolution - On a form of spurious correlation which may arise when indices are used in the measurement of organs
79. Spurious correlation and the fallacy of the ratio standard revisited
80. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: Assessment and implications for epidemiology